Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.49 |
| ▸ | CTPS1 | P17812 | 9/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24088645 | 0.82 | CTPS1 (0.39) | APLNRCTPS1ALDH1A1MEN1KMT2A | |
| SCHEMBL24088634 | 0.81 | CTPS1 (0.40) | APLNRCTPS1MEN1KMT2A | |
| SCHEMBL28970355 | 0.75 | APLNR (0.56) | APLNRALDH1A1MEN1KMT2A | |
| SCHEMBL711873 | 0.73 | ALOX12 (0.58) | ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL23139977 | 0.73 | CTPS1 (0.53) | CTPS1 | |
| SCHEMBL29083430 | 0.70 | TSHR (0.56) | APLNRALDH1A1MEN1KMT2A | |
| SCHEMBL783785 | 0.70 | APLNR (1.00) | APLNRALDH1A1MEN1KMT2A | |
| SCHEMBL354761 | 0.70 | APLNR (0.50) | APLNRALDH1A1HPGDHSD17B10MEN1 | |
| SCHEMBL353118 | 0.70 | ROCK1 (0.47) | APLNRALDH1A1MEN1KMT2A | |
| SCHEMBL21044575 | 0.69 | CTPS1 (0.60) | CTPS1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3717465-B1 | COMPOUNDS | STEP PHARMA S A S (FR) | 2026-01-21 | — | — | EP | disclosed |
| US-20230183229-A1 | Compounds | SYGNATURE DISCOVERY LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20230183229-A1 | Compounds | SYGNATURE DISCOVERY LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20210380575-A1 | COMPOUNDS | SYGNATURE DISCOVERY LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183229-A1 | Compounds | UGT1A1, CYP1A1, CYP1B1 | APLNR 3726/4885CTPS1 2556/4885ALDH1A1 158/4885 |
| US-20210380575-A1 | COMPOUNDS | UGT1A1, CYP1A1, CYP1B1 | APLNR 3726/4885CTPS1 2556/4885ALDH1A1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.